Ex vivo T cell depletion as GVHD prophylaxis

The CliniMACS® CD34 Reagent System is an FDA-approved method for selecting hematopoietic stem cells from donor apheresis, while passively depleting T cells that can cause graft-versus-host disease (GVHD). Ex vivo T cell depletion can be a viable option to reduce GVHD incidences in patients with AML undergoing allogeneic stem cell transplantation. 

If you have questions regarding the CliniMACS CD34 Reagent System, please visit the contact page for healthcare professionals or patients.

Product categories

Seems like you are coming from USA!
Do you want to visit our website in your country?